Contributing to public health

From our headquarters in Copenhagen, we develop and manufacture vaccines, diagnostics, and therapeutic solutions for the world. We are proud to contribute to disease control in more than 50 countries through our collaboration with WHO and UNICEF. We have more than 600 colleagues, and we pride ourselves on being a diverse workforce with passports from 37 nationalities.

In addition, we manufacture Tuberculin Skin Test for screening and diagnosing of high-risk patients for infection with TB, as well as BCG Culture (Danish Strain 1331) for the standard treatment of intermediate and high-risk non-muscle invasive bladder cancer (NMIBC).

Striving to eradicate polio

We are proud to be part of the Childhood Vaccination Programme and the WHO Global Polio Eradication Initiative. With our dose sparring technology we are providing a significant contribution to expanding inactivated polio vaccine supply.

Our Danish roots

AJ Vaccines was established in 2017 when Statens Serum Institut divested the production of vaccines. Since 1902, Statens Serum Institut has played a crucial role in preventing and treating major epidemics and public diseases in Denmark, providing Danes with a sense of security. Creating safety through vaccination is still at the heart of our work today.

100 years of experience

We have a history dating back to the inception of the first vaccines and childhood vaccination programs in Denmark.

Yet, AJ Vaccines is a novel company with a worldwide outlook. As we gaze into the future, we are innovating to ensure that the entire world has access to the same safety and preventative opportunities through vaccination as enjoyed in Denmark.